Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI)

Q: What does CUSIP 89532M101 represent in this 13F holders report?

CUSIP 89532M101 is the security identifier for TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share used to aggregate holder disclosures.

Q: How many institutions held TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share in Q1 2026?

55 institutional investors reported TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 89532M101

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, $0.001 par value per share
Shares outstanding: 143,562,667
Total 13F shares: 10,593,005
Share change: +1,606,718
Total reported value: $126,490,127
Price per share: $11.93
Number of holders: 55
Value change: +$19,194,364
Number of buys: 33
Number of sells: 17

Quarterly Holders Quick Answers

What is CUSIP 89532M101?
CUSIP 89532M101 identifies TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 89532M101:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
NEA Management Company, LLC	13F	Company	9.2%	13,222,228	$165,542,295	—	31 Dec 2025	13F
Frazier Life Sciences Management, L.P.	13F	Company	7.1%	10,259,409	$128,447,801	—	31 Dec 2025	13F
BlackRock, Inc.	13F 13D/G	Company	5.6% from 13D/G	10,126,183	$126,779,812	—	31 Dec 2025	13F 13D/G
FMR LLC	13D/G 13F	Company	6.3%	8,038,061	$106,022,020	+$20,286,893	31 Mar 2026	13D/G 13F
VANGUARD GROUP INC	13F	Company	4.5%	6,434,655	$80,561,880	—	31 Dec 2025	13F
Frazier Life Sciences Public Fund, L.P.	13D/G	—	7%	8,508,021	$77,848,392	-$16,025,200	30 Sep 2025	13D/G
Vivo Capital, LLC	13F	Company	3.5%	5,094,668	$63,785,243	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	3.2%	4,580,548	$57,348,462	—	31 Dec 2025	13F
Rubric Capital Management LP	13F 13D/G	Company	2.9% from 13D/G	3,766,749	$47,159,697	—	31 Dec 2025	13F 13D/G
VIKING GLOBAL INVESTORS LP	13D/G 13F	Company	4.2%	5,128,875	$46,929,206	-$21,747,894	30 Sep 2025	13D/G 13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	2.4%	3,403,990	$42,617,956	—	31 Dec 2025	13F
MPM BioImpact LLC	13F	Company	2.3%	3,287,087	$41,154,329	—	31 Dec 2025	13F
ORBIMED ADVISORS LLC	13F	Company	2.2%	3,190,700	$39,947,564	—	31 Dec 2025	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	2.1%	3,082,986	$38,598,985	—	31 Dec 2025	13F
Octagon Capital Advisors LP	13F	Company	2%	2,815,000	$35,243,800	—	31 Dec 2025	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	1.8%	2,622,306	$32,831,271	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	1.7%	2,435,000	$30,486,200	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.7%	2,412,885	$30,214,388	—	31 Dec 2025	13F
Siren, L.L.C.	13F	Individual	1.6%	2,286,867	$28,631,575	—	31 Dec 2025	13F
Affinity Asset Advisors, LLC	13F	Company	1.5%	2,150,172	$26,920,153	—	31 Dec 2025	13F
ACORN CAPITAL ADVISORS, LLC	13F	Company	1.5%	2,144,844	$26,853,447	—	31 Dec 2025	13F
Artia Global Partners LP	13F	Company	1.4%	2,013,602	$25,210,297	—	31 Dec 2025	13F
EMERALD ADVISERS, LLC	13F	Company	1.3%	1,892,276	$23,691,296	—	31 Dec 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	1.2%	1,766,963	$22,122,376	—	31 Dec 2025	13F
Logos Global Management LP	13F	Company	1.1%	1,550,000	$19,406,000	—	31 Dec 2025	13F
Pictet Asset Management Holding SA	13F	Company	1.1%	1,532,013	$19,180,803	—	31 Dec 2025	13F
Ali Behbahani	3/4/5	10%+ Owner	8.5%	12,273,280	$16,814,393	—	31 Dec 2025	3/4/5
Anthony A. Florence Jr.	3/4/5	10%+ Owner	8.5%	12,273,280	$16,814,393	—	31 Dec 2025	3/4/5
Carmen Chang	3/4/5	10%+ Owner	8.5%	12,273,280	$16,814,393	—	31 Dec 2025	3/4/5
Forest Baskett	3/4/5	10%+ Owner	8.5%	12,273,280	$16,814,393	—	31 Dec 2025	3/4/5
Mohamad Makhzoumi	3/4/5	10%+ Owner	8.5%	12,273,280	$16,814,393	—	31 Dec 2025	3/4/5
New Enterprise Associates 16, L.P.	3/4/5	10%+ Owner	8.5%	12,273,280	$16,814,393	—	31 Dec 2025	3/4/5
Paul Edward Walker	3/4/5	10%+ Owner	8.5%	12,273,280	$16,814,393	—	31 Dec 2025	3/4/5
Scott D. Sandell	3/4/5	10%+ Owner	8.5%	12,273,280	$16,814,393	—	31 Dec 2025	3/4/5
EMERALD MUTUAL FUND ADVISERS TRUST	13F	Company	0.89%	1,272,373	$15,930,110	—	31 Dec 2025	13F
Pivotal bioVenture Partners Investment Advisor LLC	13F	Company	0.88%	1,256,782	$15,734,911	—	31 Dec 2025	13F
FRONTIER CAPITAL MANAGEMENT CO LLC	13F	Company	0.77%	1,108,468	$13,878,019	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.76%	1,094,851	$13,707,534	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.74%	1,056,891	$13,232,276	—	31 Dec 2025	13F
FLPUTNAM INVESTMENT MANAGEMENT CO	13F	Company	0.73%	1,053,427	$13,188,906	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.73%	1,050,296	$13,149,707	—	31 Dec 2025	13F
Woodline Partners LP	13F	Company	0.7%	1,000,282	$12,523,531	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.7%	1,000,000	$12,520,000	—	31 Dec 2025	13F
NAN FUNG TRINITY (HK) Ltd	13F	Company	0.64%	917,450	$11,486,474	—	31 Dec 2025	13F
Soleus Capital Management, L.P.	13F	Company	0.63%	900,000	$11,268,000	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.58%	836,800	$10,476,736	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.58%	825,548	$10,335,861	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.53%	761,966	$9,539,814	—	31 Dec 2025	13F
PANAGORA ASSET MANAGEMENT INC	13F	Company	0.48%	693,001	$8,676,373	—	31 Dec 2025	13F
Venrock Healthcare Capital Partners II, L.P.	13D/G	—	1.4%	1,266,457	$8,042,002	$0	31 Dec 2024	13D/G

Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q1 2026

As of 31 Mar 2026, Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) was held by 55 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 10,593,005 shares. The largest 10 holders included EMERALD ADVISERS, LLC, Pictet Asset Management Holding SA, EMERALD MUTUAL FUND ADVISERS TRUST, NAN FUNG TRINITY (HK) LTD, FLPUTNAM INVESTMENT MANAGEMENT CO, Candriam S.C.A., PEREGRINE CAPITAL MANAGEMENT LLC, UBS Group AG, Bank of New York Mellon Corp, and Nuveen, LLC. This page lists 55 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

184

Q1 2026 holders

Holder diff

-129

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.